Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Psychiatry/Psychology | Neurology | Family Medicine
Disease Category: Depression (Major/Severe)
Location: United States, IL
A randomized, placebo-controlled, double-blind study of Ly2216684 flexible dose 12 mg to 18 mg once daily and LY2216684 fixed dose 6 mg once daily as adjunctive treatment for patients with major depressive disorder who are partial responders to selective serotonin reuptake inhibitor treatment.
The primary objective of this study is to assess whether LY2216684 (12 mg to 18 mg flexible dose QD) is better than placebo to increase the effectiveness of a patient's current medication treatment for major depressive disorder when taken once daily in addition to a patient's current stable major depression treatment.
Please contact Alexian Brothers for more information on participation.
Date Last Changed:
July 22, 2013
Alexian Brothers Hospital Network1786 Moon Lake Boulevard, Suite 200Hoffman Estates, IL 60169Phone: 847-230-3599
Research Center Information: Alexian Brothers Hospital Network
If you would like to learn more about participating in this research study, please email the trial contact using the form below.
DISCLAIMER: CenterWatch does not conduct clinical research.
CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies,
contract research organizations, clinical research sites and other interested parties. This information
is designed to help patients find clinical trials of interest and contact the research centers
conducting the trials.
Copyright © 1995-2015 CenterWatch.